open access Feb 13, 2018: The Yet Unrealized Promise of Ovarian Cancer Screening Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, February 13, 2018

open access Feb 13, 2018: The Yet Unrealized Promise of Ovarian Cancer Screening

The Yet Unrealized Promise of Ovarian Cancer Screening



US Preventive Services Task Force.  Screening for ovarian cancer: US Preventive Services Task Force recommendation statement  [published February 13, 2018].  JAMA. doi:10.1001/jama.2017.21926Google Scholar
Henderson  JT, Webber  EM, Sawaya  GF.  Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force  [published February 13, 2018].  JAMA. doi:10.1001/jama.2017.21421Google Scholar
Jacobs  IJ, Menon  U, Ryan  A,  et al.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).  Lancet. 2016;387(10022):945-956.PubMedGoogle ScholarCrossref
Buys  SS, Partridge  E, Black  A,  et al; PLCO Project Team.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial.  JAMA. 2011;305(22):2295-2303.PubMedGoogle ScholarCrossref
Jacobs  IJ, Skates  SJ, MacDonald  N,  et al.  Screening for ovarian cancer: a pilot randomised controlled trial.  Lancet. 1999;353(9160):1207-1210.PubMedGoogle ScholarCrossref
Barrett  J, Jenkins  V, Farewell  V,  et al; UKCTOCS trialists.  Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS).  BJOG. 2014;121(9):1071-1079.PubMedGoogle ScholarCrossref
American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice; Society of Gynecologic Oncology. ACOG Committee opinion No. 716, September 2017. Accessed January 22, 2018.
Marchetti  C, De Felice  F, Palaia  I,  et al.  Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all-cause mortality in BRCA 1 and BRCA 2 mutation carriers.  BMC Womens Health. 2014;14:150.PubMedGoogle ScholarCrossref
Rosenthal  AN, Fraser  LSM, Philpott  S,  et al; United Kingdom Familial Ovarian Cancer Screening Study collaborators.  Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the UK Familial Ovarian Cancer Screening Study.  J Clin Oncol. 2017;35(13):1411-1420.PubMedGoogle ScholarCrossref
Skates  SJ, Greene  MH, Buys  SS,  et al.  Early detection of ovarian cancer using the Risk of Ovarian Cancer Algorithm with frequent CA125 testing in women at increased familial risk.  Clin Cancer Res. 2017;23(14):3628-3637.PubMedGoogle ScholarCrossref
Karlan  BY, Thorpe  J, Watabayashi  K,  et al.  Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.  Cancer Epidemiol Biomarkers Prev. 2014;23(7):1383-1393.PubMedGoogle ScholarCrossref
Menon  U, McGuire  AJ, Raikou  M,  et al.  The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).  Br J Cancer. 2017;117(5):619-627.PubMedGoogle ScholarCrossref
Sieh  W, Salvador  S, McGuire  V,  et al; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium.  Tubal ligation and risk of ovarian cancer subtypes.  Int J Epidemiol. 2013;42(2):579-589.PubMedGoogle ScholarCrossref
Garcia  C, Martin  M, Tucker  LY,  et al.  Experience with opportunistic salpingectomy in a large, community-based health system in the United States.  Obstet Gynecol. 2016;128(2):277-283.PubMedGoogle ScholarCrossref
Powell  CB, Swisher  EM, Cass  I,  et al.  Long-term follow-up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.  Gynecol Oncol. 2013;129(2):364-371.PubMedGoogle ScholarCrossref
Labidi-Galy  SI, Papp  E, Hallberg  D,  et al.  High grade serous ovarian carcinomas originate in the fallopian tube.  Nat Commun. 2017;8(1):1093.PubMedGoogle ScholarCrossref


Post a Comment

Your comments?